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Phosphate homeostasis is coordinated and regulated by complex cross-organ talk through delicate hormonal networks.
Parathyroid hormone (PTH), secreted in response to low serum calcium, has an important role in maintaining phosphate
homeostasis by influencing renal synthesis of 1,25-dihydroxyvitamin D, thereby increasing intestinal phosphate
absorption. Moreover, PTH can increase phosphate efflux from bone and contribute to renal phosphate homeostasis
through phosphaturic effects. In addition, PTH can induce skeletal synthesis of another potent phosphaturic hormone,
fibroblast growth factor 23 (FGF23), which is able to inhibit renal tubular phosphate reabsorption, thereby increasing
urinary phosphate excretion. FGF23 can also fine-tune vitamin D homeostasis by suppressing renal expression of 1-alpha
hydroxylase (1a(OH)ase). This review briefly discusses how FGF23, by forming a bone–kidney axis, regulates phosphate
homeostasis, and how its dysregulation can lead to phosphate toxicity that induces widespread tissue injury. We also
provide evidence to explain how phosphate toxicity related to dietary phosphorus overload may facilitate incidence of
noncommunicable diseases including kidney disease, cardiovascular disease, cancers and skeletal disorders.
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Introduction
All living organisms are dependent on exogenous sources of
phosphorus. In humans and animals, dietary phosphorus must
be acquired in sufficient amounts to avoid nutrition-related
deficiencies such as rickets. In the body, exogenous phos-
phorus is metabolized to phosphate. Dietary phosphorus
overload may contribute to dysregulation of phosphate
metabolism leading to phosphate toxicity.1 In this review, we
discuss the regulation of phosphate metabolism, and how its
dysregulation can lead to phosphate toxicity. We define
phosphate toxicity as excessive levels of extracellular and
intracellular phosphate that are harmful to cellular function. In
addition, several conditions associated with phosphate toxicity
such as ectopic calcification, chronic kidney disease (CKD) and
tumorigenesis are discussed.
The active roles of calciotropic hormones vitamin D and
parathyroid hormone (PTH) to regulate phosphate homeostasis
are well known.2,3 However, physiologic phosphate regulation
cannot be fully explained by the actions of these hormones
alone,4–8 and the identification of fibroblast growth factor 23
(FGF23), which can influence both vitamin D and PTH functions,
helped us gain further insights into the physiologic regulation
of phosphate homeostasis. Skeletal-derived FGF23 exerts
phosphate-lowering effects in the kidney via a complex
endocrine network; studies have identified osteoblasts and
osteocytes as the main FGF23-producing cells.9,10 In addition
to renal phosphate-lowering effects, FGF23 can lower
1,25-dihydroxyvitamin D production by suppressing the renal
expression of 1-alpha hydroxylase (1a(OH)ase) and by
increasing catabolism in the kidney. Studies have claimed that
FGF23 may also suppress PTH synthesis.
FGF23 mediates its functions by interacting with an FGF
receptor (FGFR) in a dependent manner using alpha-klotho as a
cofactor. Although almost all tissues and organs express one or
more isoforms of FGFRs, the restricted presence of alpha-
klotho provides organ specificity to FGF23 functions.11–14
FGF23 was initially identified in the ventrolateral thalamic
nucleus of the mouse brain,15 and its clinical importance was
subsequently shown in patients with autosomal dominant
hypophosphatemic rickets.16 The FGF23 gene has three exons
separated by two introns, and the gene encodes a 32-kDa
glycoprotein containing 251 amino acid residues: 24 amino
acids constitute a hydrophobic signal sequence, an N terminus
of 155 amino acids constitute the FGF core homology region
and 72 amino acids form the C-terminal domain.17–20 After
cleavage of the 24-amino-acid signal sequence, the mature
protein (25–251)-FGF23 is secreted into the circulation
where three distinct forms of the FGF23 protein can be
Correspondence: Dr MS Razzaque, Department of Applied Oral Sciences, The Forsyth Institute, 245 First Street, Cambridge, MA 02142, USA.
E-mails: mrazzaque@forsyth.org; or msrazzaque@vpshealth.com
Received 9 October 2014; accepted 25 March 2015; published online 3 June 2015
Citation: BoneKEy Reports 4, Article number: 705 (2015) | doi:10.1038/bonekey.2015.74
& 2015 International Bone & Mineral Society All rights reserved 2047-6396/15
www.nature.com/bonekey
BoneKEy Reports | JUNE 2015 1
detected: a full-length mature form (25–251)-FGF23, a shorter
form (25–179)-FGF23 lacking the unique C-terminal tail of 72
amino acids and a C-terminal tail. The shorter form without a
C-terminal tail arises from proteolytic cleavage at the
176RXXR179 site,17–20 and it can also be detected in the serum.
Recent studies have shown that the C terminus is not only the
potential alpha-klotho-interacting site, but it also determines
the functionality of the FGF23 protein. The chimeric protein
containing the N terminus of FGF2 and C terminus of FGF23
could act as a phosphatonin and could reduce the renal
expression of 1a(OH)ase.19,20 It is worth mentioning that the
presence of the C terminus of FGF23 in the chimeric protein
paved the way for the alpha-klotho interaction. Recently, a
family with sequence similarity 20, member C (Fam20C), was
shown to phosphorylate FGF23. Such phosphorylation blocks
O-glycosylation by polypeptide N-acetylgalactosaminyl-
transferase 3. This observation suggests that the interplay
between phosphorylation and O-glycosylation of FGF23 may
be a critical posttranslational modification by which the activity
of secreted FGF23 protein is determined.21 Once secreted,
FGF23 protein binds its receptors to exert diverse functions.
In vitro studies have shown that bioactive FGF23 protein can
bind to FGFR1c, FGFR3c and FGFR4, but not to FGFR2c.22
In vivo studies have suggested that FGFR1c is the main target
for FGF23 in the kidney23,24, as loss of FGFR3 or FGFR4 activity
did not affect FGF23-mediated hypophosphatemia in Hyp
mice.24 It is of relevance that Hyp mouse is the model for human
X-linked hypophosphatemia related to mutations that inactivate
the endopeptidases of the X chromosome (PHEX); the
inactivation of PHEX leads to increased serum levels of FGF23,
a phosphaturic hormone that induces excessive renal phos-
phate excretion and severe hypophosphatemia. Moreover,
conditional deletion of FGFR1 in the kidney abolished phos-
phaturic effects of recombinant FGF23 administration.25 It is of
relevance that no such abolition following administration of
recombinant FGF23 was noted in FGFR3 or FGFR4 knockout
mice.25 The in vivo functions of FGF23 are also elegantly
demonstrated in genetically modified mouse models. For
instance, FGF23 knockout mice develop severe hyper-
phosphatemia owing to increased renal reabsoption of
phosphate,26,27 whereas FGF23-overproducing transgenic
mice or Hyp mice are hypophosphatemic owing to excessive
urinary phosphate excretion.28,29 Such FGF23-mediated
hypophosphatemia is an alpha-klotho-dependent phenom-
enon, and miscommunication of FGF23 and alpha-klotho can
lead to dysregulation of renal phosphate homeostasis.1,14,30,31
Renal Phosphate Regulation
Under normal physiologic conditions, the kidneys maintain
serum phosphate balance by fine-tuning urinary phosphate
excretion. Filtrated phosphate is reabsorbed in the renal
proximal tubular epithelial cells using sodium-dependent
phosphate (Na/Pi) cotransporters32–34 (Figure 1). Although
these cells contain three types of Na/Pi cotransporters, the type
2 cotransporter family that includes Na/Pi2a (encoded by the
SLC34a1 gene) and NaPi2c (encoded by the SLC34a3 gene) is
believed to be most active in renal phosphate uptake. In
contrast to the type 2 cotransporter system, the type 1
cotransporter (NPT1) is mostly an anion carrier, whereas the
type 3 cotransporter system comprises two transporters, PiT1
(encoded by the SLC20a1 gene) and PiT2 (encoded by the
SLC20a2 gene), and their role in phosphate transport is an
active area of research. Studies have shown that FGF23 could
suppress the expression of Na/Pi2a and Na/Pi2c, leading to less
renal phosphate uptake with increased urinary phosphate
excretion.25 In fact, transgenic mice overexpressing FGF23
showed severe urinary phosphate wasting owing to sup-
pressed expression and reduced activity of renal Na/Pi2a,28,29
whereas Fgf23 knockout mice develop severe hyperphos-
phatemia owing to increased renal expression and activity of
Na/Pi2a.26,27 It is of particular interest that genetically restoring
FGF23 systemic actions in Fgf23 knockout mice reduced
Na/Pi2a activity, resulting in reversal of hyperphosphatemia to
hypophosphatemia.29 It is important to note that the segment of
the nephron on which FGF23 exerts its most potent effects is
not yet clear, as alpha-klotho, the cofactor for FGF23 bio-
activities, is mostly present in the distal convoluted tubule,
whereas Na/Pi cotransporter activity and vitamin D metabo-
lizing enzymes are mainly present in the proximal tubular
epithelial cells.35 Although further studies are needed to
determine the exact molecular mechanisms of FGF23-medi-
ated renal phosphate transport, miscommunication between
FGF23 and alpha-klotho leads to altered phosphate balance.
Pathological conditions in CKD are mostly owing to mis-
communication between bone-derived FGF23 and kidney-
derived alpha-klotho, which leads to the development of
phosphate toxicity. In CKD patients, reduced levels of alpha-
klotho leaves FGF23 nonfunctional, thereby limiting the
kidneys’ ability to excrete urinary phosphate. In vivo studies
conducted on Fgf23 knockout mice have shown that bioactive
FGF23 protein could significantly reduce serum phosphate level
in these mutant mice. It is of particular significance that
bioactive FGF23 protein failed to exert phosphate-lowering
effects in Fgf23/alpha-klotho double knockout mice,36,37
suggesting that FGF23 loses its phosphate regulating abilities
without alpha-klotho. Moreover, FGF23-induced hypopho-
sphatemia in Hyp mice is reversed to hyperphosphatemia in the
Hyp mice without alpha-klotho activity (Hyp/alpha-klotho
double mutant mice), despite high serum FGF23 levels in
double mutant mice.3,36 In accordance with these animal
studies, an inactivating mutation in the human alpha-klotho
gene resulted in severe hyperphosphatemia, despite high
serum FGF23 levels in a patient with tumoral calcinosis.38 From
the above-cited human and experimental studies, it is clear that
alpha-klotho has an indispensable role in FGF23-mediated
phosphate metabolism.14,17,18,36,39,40 As mentioned, features
of phosphate toxicity appear in various organs when there is a
dysregulation of the FGF23-alpha-klotho system.
Phosphate Toxicity
Phosphate toxicity arising from a disproportionate accumu-
lation of phosphate in the body has been shown to accelerate
mammalian aging, produce bone deformities and reduce
overall survival.41 Genetically altered alpha-klotho-knockout
mice develop phosphate toxicity as early as at 3 weeks of age,
which affects weight gain and the bone maturation process,
produces a generalized soft tissue atrophy and results in
reduced life span.1,14,40–46 In vivo studies found that phosphate
toxicity in alpha-klotho ablated mice is associated with
increased renal activity of NaPi2a. However, phosphate
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burden was lowered in hyperphosphatemic alpha-klotho-
knockout mice by generating NaPi2a/alpha-klotho double-
knockout mice, which resulted in prolonged survival.41 More
importantly, compared with a normal-phosphate diet (0.6%),
phosphate toxicity reappeared when a high-phosphate diet
(1.2%) was fed to NaPi2a/alpha-klotho mutant mice, with the
appearance of premature aging-like features leading to early
death.41 These in vivo experimental observations clearly
suggest that phosphate toxicity related to diet can contribute to
the progression of the mammalian aging process, affecting both
bone health and overall survival.
Phosphorous has a very strong electronegative attraction
with calcium—having electronegative values on the Pauling
scale of 2.1 for phosphorus and 1.0 for calcium.47 The strength
of this attraction may help explain why phosphate toxicity owing
to dietary phosphorus overload can so easily impair calcium
metabolism. The chemical bonding of phosphorus with calcium
is most evident in the body’s hydroxyapatite mineral matrix of
bone. These two minerals normally unite to form bone tissue in a
calcium:phosphorus ratio of approximately 2:1 by weight,
averaging 2.07:1 in spongy trabecular bone tissue48 and 2.17:1
in harder cortical bone tissue.49 Of relevance, the mean
calcium:phosphorus ratio in studies of human milk is
approximately in the range of 2:1 by weight.50
Referring to the calcium:phosphorus ratio, the Food and
Nutrition Board that set the recommended dietary allowances
(RDAs) as part of the Dietary Reference Intakes51 noted that
‘there is little or no evidence for relating the two nutrients, one to
the other, during most of human life (p.154).’ Nevertheless, the
RDA that the Board set for calcium relative to that of phosphorus
is equivalent to an ample calcium:phosphorus ratio of 1.4:1 for
adults and 1.7:1 for adults aged 50 years and over. However,
data from NHANES III reported by Chang et al.52 showed
average intakes of 758 mg of calcium and 1242 mg of phos-
phorus for adults, which is equivalent to an average cal-
cium:phosphorus ratio of only 0.61:1. As noted by Uribarri and
Calvo,,53 the data reported by Chang et al.52 show a consistent
association between increasing mortality in adult subjects and a
decreasing calcium:phosphorus ratio as dietary phosphorus
intake increases more than calcium intake.
In an earlier study, calcium retention increased when college
women consumed 1500 mg of calcium and 800 mg of phos-
phorus with a calcium:phosphorus ratio of 1.88:1; however,
increasing subjects’ phosphorus intake to 1400 mg with a
calcium:phosphorus ratio of 1.07:1 significantly reduced cal-
cium utilization.54 More recent research showed that
decreasing the calcium:phosphorus ratio in a diet fed to young
women by increasing phosphorus intake disrupted calcium
metabolism, resulting in increased bone resorption as indicated
by higher levels of serum PTH and urinary calcium.55
Researchers used a calcium-adequate diet in an experimental
animal model to demonstrate how lowering the calcium:
phosphorus ratio by increasing the diet’s phosphorus content
produced defects in tooth enamel and dentin.56 The findings of
these studies imply that lowering excessive phosphorus intake
rather than increasing calcium intake beyond adequate levels is
required to properly balance the dietary calcium:phosphorus
ratio. Unfortunately, the US adult population’s average calcium
intake of 758 mg reported by Chang et al.52 is below RDA levels
of 1000 mg and 1200 mg calcium for adults 50 years and older.
Generally, the USDA Dietary Guidelines for Americans is
incongruous with the latest findings on dietary phosphorus
overload, with little indication for change in the 2015 Dietary
Guidelines.57 For example, a 2000-calorie eating pattern
recommended by the MyPlate program of the USDA Center for
Nutrition Policy & Promotion58 averages 1884 mg of phos-
phorus a day—a daily overload far above the intake level where
mortality effects are seen. Of particular concern, unrestricted
consumption of phosphate can induce systemic complications
related to phosphate toxicity (Table 1).
Phosphate Toxicity Associated with Ectopic Calcification
Calcium–phosphorus (CaxPi) product in serum, calculated by
multiplying serum calcium and phosphorus levels, should be
less than 55 mg2 dl 2 in adults.59 CaxPi product and other
anions containing calcium normally account for 5% of serum
calcium, whereas free ionized calcium accounts for 45% of
serum calcium and the remaining serum calcium is bonded
to albumin.60 Elevated levels of serum phosphorus in
hyperphosphatemia—associated with impaired kidney func-
tion, dietary phosphorus overload or both—unite with free
calcium to form an additional CaxPi product. Accumlated
excess CaxPi product is likely to be deposited into soft tissue
causing ectopic calcification.61 In addition, elevated serum
levels of osteocalcin, a noncollagenous bone matrix protein and
a marker for osteoblast function, are associated with FGF23
levels.62 Osteocalcin is also found in calcified atherosclerotic
Figure 1 Simplified diagram showing multiorgan interactions in the regulation of
phosphate homeostasis. Fibroblast growth factor (FGF) 23 produced in the bone cells
can suppress renal Na/Pi2a and Na/Pi2c cotransporter activities to increase the urinary
excretion of phosphate. Similarly, FGF23 can also suppress renal expression of 1-alpha
hydroxylase (1a(OH)ase) to reduce the production of 1,25-dihydroxyvitamin D
(1,25(OH)2D), which can suppress intestinal NaPi2b activities to reduce phosphate
absorption, resulting in decreased serum phosphate levels. Of relevance, parathyroid
hormone (PTH) can induce the expression of the 1a(OH)ase, and thereby it can
increase the production of 1,25(OH)2D, which in turn can inhibit PTH and 1a(OH)ase
expression. Such transcriptional repression feedback maintains vitamin D homeostasis.
The figure is adopted with modification from our earlier publication.1,45 (Dashed lines
indicate that the interactions either might not be direct or not scientifically validated by
multiple groups).
Phosphate toxicity
RB Brown et al
BoneKEy Reports | JUNE 2015 3
plaque.63 These associations provide evidence that rising
serum calcium–phosphate product associated with hyper-
phosphatemia upregulates osteocalcin, which stimulates
mineral deposition in soft tissue as ectopic calcification. An
opposite action is seen in the protein osteopontin, which inhibits
mineral deposition and regresses calcification.64 Vascular
calcification in rats reversed when they were switched to a
low-phosphate diet, which the researchers suggested was
associated with calcification inhibition by osteopontin.65
One type of soft tissue that is susceptible to ectopic
calcification from the deposition of CaxPi product is the
endothelium of the arterial system. Arterial calcification
increases mortality risk by threefold to fourfold.66 Calcification
causes a hard or stable plaque to form in arterial vessels, which
is related to arteriolosclerosis, hypertension, left ventricular
hypertrophy and aortic valve disease. In vitro and in vivo
experiments showed that a high phosphorus load acutely
increases endothelial dysfunction by impairing vasodilation,
raising the risk for cardiovascular disease.67 High levels of
serum phosphorus in healthy young adults have been asso-
ciated with coronary atherosclerosis68 and with left ventricular
hypertrophy,69 and high levels of serum phosphorus in a cohort
study were associated with a 40% greater risk of heart failure.70
A meta-analysis showed that serum phosphorus, but not
serum calcium or PTH, was independently associated with
mortality and risk for cardiovascular disease in CKD patients.71
Dietary phosphorus overload was found to raise systolic blood
pressure, except from dairy products, which researchers
attributed to nutrients in dairy other than phosphorus.72
The exact molecular mechanisms of how extracellular
phosphate might exert its cytotoxicity is not yet clearly defined.
Studies, however, have shown that extracellular phosphate can
form insoluble nanoparticles with calcium and fetuin-A,
commonly referred to as calciprotein particles (CPPs); these
CPPs are highly bioactive ligands that can induce cytotoxicity,
ranging from cell death to including osteogenic transformation
of vascular smooth muscle cells (VSMCs). Furthermore, CPPs
are detected in the circulation, both in human and animal
models, particularly in patients with CKD, implicating a role in
phosphate-mediated tissue injuries.73 Calcium phosphate and
other crystals may be deposited in joints causing acute
inflammation and damaged cartilage.74 Mice fed high-
phosphate diets developed ectopic tumoral calcifications
around joints.75 Other types of ectopic calcifications from
calcium phosphate occur in the formation of kidney stones,
often in combination with calcium oxalate,76 in bone tissue
irregularities such as bone spurs or osteophytes77 and within
visceral organs and the epidermis.61 Vascular calcification is a
complex, ectopic biomineralization process, and phosphate
toxicity can not only facilitate essential hydroxyapatite
deposition in the calcifying vessels but also initiate the early
events of apoptotic cell death, which is inflicted on both
endothelial cells and VSMCs. Studies have shown higher risk
for cardiovascular mortality in CKD patients undergoing
hemodialysis treatment.
Phosphate Toxicity Associated with CKD
The estimated prevalence of CKD within the global population is
8–16%.78 The role of phosphate toxicity in the pathology of CKD
and beyond is published elsewhere.1,45,73,79 A high con-
centration of extracellular phosphate is toxic to cells, and it
leads to premature cellular aging. The kidneys regulate urinary
excretion of phosphate to maintain the serum phosphate level
that is circulated throughout the body. Dietary phosphate
overload can lead to an increased phosphate burden, and it
damages the kidneys through tubular injury and interstitial
fibrosis; studies have found that subjects with high serum
phosphorus had a higher risk for developing kidney diseases.80
Glomerular filtration rate decreases as serum phosphorus
increases in kidney disease, and mortality from associated
cardiovascular disease in dialysis patients is 20% annually.
Of relevance, renal aging can accelerate systemic aging.81
As mentioned, increased serum calcium and phosphate
levels are usually considered main contributors to vascular
calcification, and the estimation of CaxPi product has long been
used to predict vascular pathology in CKD patients.82 However,
recent studies have found that serum phosphate levels in
patients undergoing hemodialysis treatment correlates with
vascular calcification more strongly than does the CaxPi
product.83 In fact, the clinical utility of the CaxPi product has
been questioned in recent studies, noting that the cause of
calcification is more complicated than just the precipitation of
the CaxPi product.84 It is of clinical relevance that, in contrast to
hyperphosphatemia, associations between serum calcium
levels and cardiovascular events or disease outcomes of CKD
patients are not yet clearly established. However, a few studies































Please note that metabolic acidosis can induce either hypophosphatemia or
hyperphosphatemia depending on clinical situations. It is believed that nonlactic
metabolic acidosis associated with hypophosphatemia can be connected to
impaired tubular reabsorption of bicarbonate and that phosphorus administration
can improve such acidosis.103 On the other hand, respiratory or metabolic
acidosis may hydrolyze intracellular organic phosphate-containing compounds
and release them into the extracellular compartment. Cell lysis disorders, such as
tumor lysis syndrome, hemolytic anemia and rhabdomyolysis, may all give rise to
hyperphosphatemia.104
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have shown that hypercalcemia may have predictive value in
determining the negative outcome of CKD patients.85
Although phosphate toxicity is known to promote disease
progression in patients with CKD, its association with tumor-
igenesis is not studied in similar depth and detail. We next
present evidence of this association and suggest some
innovative theories of tumorigenesis. We believe that these
suggestions are not based on deductive speculation, but
rather on inductive theory generation grounded in reliable
evidence.
Phosphate Toxicity Associated with Tumorigenesis
Hippocrates first observed that vessels attached to tumors
appeared like legs on a crab. Thus, the name cancer, derived
from the Latin word for crab, came into use to describe tumors.86
Today, the elaborate vessel system of tumors is considered to be
complicit with the aggressive tendency for neoplasms to grow
uncontrollably and metastasize throughout the body. However, a
novel theory of tumor vessel function may be induced from
biological findings related to phosphate toxicity. In biology, the
mycorrhiza fungal root system of plants absorbs and sequesters
phosphorus from soil.87 Evidence suggests that tumor vessels
may function similarly inhumans toabsorband sequesterexcess
phosphorus from extracellular fluid. Cancer patients have been
observed to retain and store phosphorus in tumors,88 and cancer
cells accumulate up to twice as much phosphorus as normal
cells.89 Just as tumorigenesis in tomato plants has been
positively associated with phosphorus,90 a cellular environment
high in phosphorus in humans has been found to induce tumor
neovascularization and angiogenesis, or new blood vessel
formation in neoplasms.91
Dietary phosphorus overload has been found to stimulate
tumor growth in lung tissue.92 Increasing phosphorus levels in
cultured breast cancer cells were observed to change cellular
behavior and metabolism, thus supporting the role of inorganic
phosphate in modulating tumor metabolism and metastasis.93
An average daily phosphorus intake of 1395 mg in men followed
up for 22 years in the Health Professionals Follow-Up Study was
associated with an increased overall risk of prostate cancer
and with lethal and high-grade prostate cancer.94 Farmers of
Liuchong Village in the Hubei province of China claimed that
cancer cases increased in their village from drinking water
contaminated by a nearby phosphate mine.95
Many studies have examined the association of meat and
dairy intake with cancer, but a review of meta-analyses showed
inconsistent findings.96 Few studies have examined the
phosphate intake from meat and dairy in association with
cancer. In addition, it is difficult to isolate the effect of phos-
phorus in one or two foods without considering the total
phosphate content of the diet. For example, subjects with high
intake of dietary phosphate from meat and dairy but with overall
normal phosphate intake may show less increase in cancer
incidence than subjects with low intake of phosphate from
meat and dairy but with a high overall phosphate intake.
Comparisons of diets containing similar amounts of total
phosphate at baseline should be investigated for cancer risk as
the phosphate content rises from meat and dairy intake.
From the above-mentioned evidence, it is likely that dietary
phosphate consumption might influence tumorigenesis,
possibly as a storage mechanism to help maintain phosphate
homeostasis, and further research using meaningful
experimental designs is warranted to validate such speculation.
Conclusion
The endocrine communication between bone-derived FGF23
and kidney-derived alpha-klotho is essential for physiologic
regulation of phosphate balance. As we have briefly discussed,
dysregulation of FGF23/alpha-klotho system provokes phos-
phate imbalance and induces a wide range of organs/tissue
damage in blood vessels, bone and kidney. Of clinical
importance, phosphate toxicity induced by excessive exo-
genous phosphate administration in humans can be fatal.97–99
In fact, it is becoming more evident from experimental and
human observations that features of phosphate toxicity can
appear after consumption of a high-phosphate diet, even when
serum phosphate levels are within the normal range.3,43,45,79
Recent survey results highlight that even future medical pro-
fessionals and CKD patients undergoing hemodialysis are not
adequately aware of the hidden source of phosphate in their
diet, and emphasize the need for educational initiatives to raise
awareness of the risk posed by dietary items with hidden
phosphate ingredients.100,101 Taking into account human and
animal observations, maintaining phosphate balance through
adequate dietary intake appears to be important for a healthy
life and for longevity. In addition, phosphate imbalance owing to
bone–kidney miscommunication can induce serious debili-
tating complications.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements
Part of the original research that formed the basis of this review
article was performed by Razzaque’s lab members (Drs Teruyo
Nakatani, Junko Akiyoshi, Satoko Osuka, Shigeko Kato,
Kazuyoshi Uchihashi and Mutsuko Ohnishi) at the Harvard
School of Dental Medicine, Boston, MA, USA.
References
1. Razzaque MS. Phosphate toxicity: new insights into an old problem. Clin Sci (Lond) 2011;
120: 91–97.
2. Rodriguez M, Felsenfeld AJ. PTH, FGF-23 and early CKD. Nephrol Dial Transplant 2008; 23:
3391–3393.
3. Razzaque MS. Osteo-renal regulation of systemic phosphate metabolism. IUBMB Life 2011;
63: 240–247.
4. Patel S, Barron JL, Mirzazedeh M, Gallagher H, Hyer S, Cantor T et al. Changes in bone
mineral parameters, vitamin D metabolites, and PTH measurements with varying chronic
kidney disease stages. J Bone Miner Metab 2011; 29: 71–79.
5. Evenepoel P, Viaene L, Meijers B. PTH, FGF23, and calcium: it takes three to tango? Kidney
Int 2011; 80: 1377.
6. Lanske B, Razzaque MS. Molecular interactions of FGF23 and PTH in phosphate regulation.
Kidney Int 2014; 86: 1072–1074.
7. Brown RB, Haq A, Stanford CF, Razzaque MS. Vitamin D, phosphate and vasculotoxicity.
Can J Physiol Pharmacol 2015; doi:10.1139/cjpp-2015-0083.
8. Burnett-Bowie SM, Henao MP, Dere ME, Lee H, Leder BZ. Effects of hPTH(1-34) infusion on
circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men.
J Bone Miner Res 2009; 24: 1681–1685.
9. Sitara D, Razzaque MS, St-Arnaud R, Huang W, Taguchi T, Erben RG et al. Genetic ablation
of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null
animals. Am J Pathol 2006; 169: 2161–2170.
10. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B et al. Loss of DMP1 causes rickets and
osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38:
1310–1315.
Phosphate toxicity
RB Brown et al
BoneKEy Reports | JUNE 2015 5
11. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine
pathways. Physiol Rev 2012; 92: 131–155.
12. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and
pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75:
503–533.
13. Ohnishi M, Razzaque MS. Osteo-renal cross-talk and phosphate metabolism by the
FGF23-Klotho system. Contrib Nephrol 2013; 180: 1–13.
14. Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat
Rev Endocrinol 2009; 5: 611–619.
15. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23,
preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys
Res Commun 2000; 277: 494–498.
16. ADHR_Consortium. Autosomal dominant hypophosphataemic rickets is associated with
mutations in FGF23. The ADHR Consortium. Nat Genet 2000; 26: 345–348.
17. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV et al. Molecular
insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19
subfamily members. Mol Cell Biol 2007; 27: 3417–3428.
18. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T et al. Isolated C-terminal tail of
FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.
Proc Natl Acad Sci USA 2010; 107: 407–412.
19. Goetz R, Ohnishi M, Ding X, Kurosu H, Wang L, Akiyoshi J et al. Klotho coreceptors inhibit
signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol Cell Biol 2012; 32:
1944–1954.
20. Goetz R, Ohnishi M, Kir S, Kurosu H, Wang L, Pastor J et al. Conversion of a paracrine
fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem 2012; 287:
29134–29146.
21. Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, Nidumanda Appaiah H et al.
Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and
furin proteolysis. Proc Natl Acad Sci USA 2014; 111: 5520–5525.
22. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor
activation. Cytokine Growth Factor Rev 2005; 16: 107–137.
23. Li H, Martin A, David V, Quarles LD. Compound deletion of Fgfr3 and Fgfr4 partially rescues
the Hyp mouse phenotype. Am J Physiol Endocrinol Metab 2011; 300: E508–E517.
24. Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD. FGFR3 and FGFR4 do not mediate renal
effects of FGF23. J Am Soc Nephrol 2008; 19: 2342–2350.
25. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R et al. FGF23
decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo
predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009; 297: F282–F291.
26. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T et al. Targeted
ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and
vitamin D metabolism. J Clin Invest 2004; 113: 561–568.
27. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG et al. Homozygous
ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skele-
togenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23:
421–432.
28. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T et al. FGF-23 transgenic
mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate
cotransporter type IIa. Biochem Biophys Res Commun 2004; 314: 409–414.
29. DeLuca S, Sitara D, Kang K, Marsell R, Jonsson K, Taguchi T et al. Amelioration of the
premature ageing-like features of Fgf-23 knockout mice by genetically restoring the systemic
actions of FGF-23. J Pathol 2008; 216: 345–355.
30. Lanske B, Razzaque MS. Mineral metabolism and aging: the fibroblast growth factor 23
enigma. Curr Opin Nephrol Hypertens 2007; 16: 311–318.
31. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in
renal regulation of phosphate homeostasis. J Endocrinol 2007; 194: 1–10.
32. Tenenhouse HS. Regulation of phosphorus homeostasis by the type iia na/phosphate
cotransporter. Annu Rev Nutr 2005; 25: 197–214.
33. Tenenhouse HS, Martel J, Gauthier C, Segawa H, Miyamoto KI. Differential effects of Npt2a
gene ablation and the X-linked Hyp mutation on renal expression of type IIc Na/Pi
cotransporter. Am J Physiol Renal Physiol 2003; 2: 2.
34. Miyamoto KI, Haito-Sugino S, Kuwahara S, Ohi A, Nomura K, Ito M et al. Sodium-dependent
phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci
2011; 100: 3719–3730.
35. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M et al. Fibroblast growth factor 23 is a counter-
regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305–1315.
36. Nakatani T, Ohnishi M, Razzaque MS. Inactivation of klotho function induces hyperpho-
sphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically
engineered hypophosphatemic (Hyp) mouse model. FASEB J 2009; 23: 3702–3711.
37. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R et al. In vivo genetic
evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of
systemic phosphate homeostasis. FASEB J 2009; 23: 433–441.
38. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH et al. A homozygous
missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007;
117: 2684–2691.
39. Razzaque MS. Does FGF23 toxicity influence the outcome of chronic kidney disease?
Nephrol Dial Transplant 2009; 24: 4–7.
40. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an
essential player? Am J Physiol Renal Physiol 2009; 296: F470–F476.
41. Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity accelerating
mammalian aging. FASEB J 2010; 24: 3562–3571.
42. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. Mutation of the
mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45–51.
43. Razzaque MS. Bone-kidney axis in systemic phosphate turnover. Arch Biochem Biophys
2014; 561: 154–158.
44. Nabeshima Y, Washida M, Tamura M, Maeno A, Ohnishi M, Shiroishi T et al. Calpain 1
inhibitor BDA-410 ameliorates alpha-klotho-deficiency phenotypes resembling human aging-
related syndromes. Sci Rep 2014; 4: 5847.
45. Osuka S, Razzaque MS. Can features of phosphate toxicity appear in normophosphatemia?
J Bone Miner Metab 2012; 30: 10–18.
46. Lanske B, Razzaque MS. Premature aging in klotho mutant mice: cause or consequence?
Ageing Res Rev 2007; 6: 73–79.
47. Brown TL, LeMay HEJ, Bursten BE, Murphy CJ, Woodward PM. Bond polarity and
electonegativity. In Chemisty: The Central Science. 12th edn (Pearson Prentice Hall: Boston,
MA, USA, 2012, pp288–329.
48. Zaichick V, Tzaphlidou M. Calcium and phosphorus concentrations and the calcium/
phosphorus ratio in trabecular bone from the femoral neck of healthy humans as determined
by neutron activation analysis. Appl Radiat Isot 2003; 58: 623–627.
49. Zaichick V, Tzaphlidou M. Determination of calcium, phosphorus, and the calcium/
phosphorus ratio in cortical bone from the human femoral neck by neutron activation analysis.
Appl Radiat Isot 2002; 56: 781–786.
50. Jenness R. The composition of human milk. Semin Perinatol 1979; 3: 225–239.
51. IOM. Dietary Reference Intakes For Calcium, Phosphorus, Magnesium, Vitamin D, and
Fluoride. The National Academies Press: Washington, DC, USA, 1997.
52. Chang AR, Lazo M, Appel LJ, Gutierrez OM, Grams ME. High dietary phosphorus intake
is associated with all-cause mortality: results from NHANES III. Am J Clin Nutr 2014; 99:
320–327.
53. Uribarri J, Calvo MS. Dietary phosphorus intake and health. Am J Clin Nutr 2014; 99: 247–248.
54. Leichsenring JM, Norris LM, Lamison SA. The effect of level of intake on calcium and
phosphorus metabolism in college women. J Nutr 1951; 45: 407–418.
55. Kemi VE, Karkkainen MU, Rita HJ, Laaksonen MM, Outila TA, Lamberg-Allardt CJ. Low
calcium:phosphorus ratio in habitual diets affects serum parathyroid hormone concentration
and calcium metabolism in healthy women with adequate calcium intake. Br J Nutr 2010; 103:
561–568.
56. Jekl V, Krejcirova L, Buchtova M, Knotek Z. Effect of high phosphorus diet on tooth
microstructure of rodent incisors. Bone 2011; 49: 479–484.
57. Hennessy M. Until phosphorus gets on the USDA’s radar labeling policy won’t change: NKF
2014 http://www.foodnavigator-usa.com/Regulation/Until-phosphorus-gets-on-the-USDA-s-
radar-labeling-policy-won-t-change-NKF.
58. CNPP 2011, MyPlate: Sample menus for a 2000 calorie food pattern http://www.
choosemyplate.gov/food-groups/downloads/Sample_Menus-2000Cals-DG2010.pdf.
59. NKF 2003, KDOQI clinical practice guidelines for bone metabolism and disease in chronic
kidney disease: Guideline 6. Serum calcium and calcium-phosphorus product.
60. Mihai R, Farndon JR. Parathyroid disease and calcium metabolism. Br J Anaesth 2000; 85:
29–43.
61. NKF 2003b, KDOQI clinical practice guidelines for bone metabolism and disease in chronic
kidney disease: background.
62. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate
and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90:
1519–1524.
63. Foresta C, Strapazzon G, De Toni L, Fabris F, Grego F, Gerosa G et al. Platelets express and
release osteocalcin and co-localize in human calcified atherosclerotic plaques. J Thromb
Haemost 2013; 11: 357–365.
64. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H et al. Osteopontin inhibits
mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002; 161:
2035–2046.
65. Finch JL, Lee DH, Liapis H, Ritter C, Zhang S, Suarez E et al. Phosphate restriction
significantly reduces mortality in uremic rats with established vascular calcification. Kidney Int
2013; 84: 1145–1153.
66. Rennenberg R. J. M. W., Kessels AGH, Schurgers LJ, Engelshoven JMA, Leeuw PW, Kroon
AA. Vascular calcifications as a marker of increased cardiovascular risk: a meta analysis. Vasc
Health Risk Manag 2009; 5: 185–197.
67. Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M et al. Dietary phosphorus acutely
impairs endothelial function. J Am Soc Nephrol 2009; 20: 1504–1512.
68. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with
coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397–404.
69. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus and left ventricular
hypertrophy in young adults: the coronary artery risk development in young adults study. J Am
Soc Nephrol 2009b; 20: 397–404.
70. Lutsey PL, Alonso A, Michos ED, Loehr LR, Astor BC, Coresh J et al. Serum magnesium,
phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis
Risk in Communities (ARIC) Study. Am J Clin Nutr 2014; 100: 756–764.
71. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ et al. Serum levels of
phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease
in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA
2011; 305: 1119–1127.
Phosphate toxicity
RB Brown et al
6 JUNE 2015 | www.nature.com/bonekey
72. Alonso A, Nettleton JA, Ix JH, Boer IH, Folsom AR, Bidulescu A et al. Dietary phosphorus,
blood pressure and incidence of hypertension in the Atherosclerosis Risk in Communities
(ARIC) Study and the Multi-Ethnic Study of Atherosclerosis (MESA). Hypertension 2010; 55:
776–784.
73. Kuro-o M. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney
disease. Kidney Int Suppl 2013; 3: 420–426.
74. Oliviero F, Scanu A, Punzi L. Metabolism of crystals within the joint. Reumatismo 2011; 63:
221–229.
75. Ichikawa S, Gray AK, Padgett LR, Reilly AM, Unsicker TR. High dietary phosphate intake
induces development of ectopic calcifications in a murine model of familial tumoral calcinosis.
J Bone Miner Res 2014; 29: 2017–2023.
76. Worcester EM, Coe FL. Calcium kidney stones. N Engl J Med 2010; 363: 954–963.
77. Omoto M, Imai T, Seki K, Nomura R, Otahara Y. The effect on the bones of condensed
phosphate when used as food additives: its importance in relation to preventive medicine.
Environ Health Prev Med 1997; 2: 105–116.
78. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B et al. Chronic kidney disease:
global dimension and perspectives. Lancet 2013; 382: 260–272.
79. Razzaque MS. Phosphate toxicity and vascular mineralization. Contrib Nephrol 2013; 180:
74–85.
80. Uribarri J. Dietary phosphorus and kidney disease. Ann NY Acad Sci 2013; 1301: 11–19.
81. Razzaque MS. Does renal ageing affect survival? Ageing Res Rev 2007; 6: 211–222.
82. Stompor TP, Pasowicz M, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K et al. Trends
and dynamics of changes in calcification score over the 1-year observation period in patients
on peritoneal dialysis. Am J Kidney Dis 2004; 44: 517–528.
83. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary
artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006; 21:
1915–1920.
84. O’Neill WC. Vascular calcification: not so crystal clear. Kidney Int 2007; 71: 282–283.
85. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardio-
vascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc
Nephrol 2005; 16: 1788–1793.
86. cancer.org. (2014c) The history of cancer..
87. Jansa J, Finaly R, Wallander H, Smith FA, Smith SE. Role of mycorrhizal symbioses in
phosphorus cycling. In: Phosphorus in Action: Biological Processes in Soil Phosphorus
Cycling. (eds Bünemann EK, Oberson A, Frossard E) 137–168 (Springer: Heidelberg,
Germany, 2011).
88. Fenninger LD, Waterhouse C, Keutmann EH. The interrelationship of nitrogen and
phosphorus in patients with certain neoplastic diseases. Cancer 1953; 5: 930–941.
89. Elser JJ, Kyle MM, Smith MS, Nagy JD. Biological stoichiometry in human cancer. PLoS One
2007; 2: e1028.
90. Swain LW, Rier JPJ. Tumorigenesis on mineral deficient tomato plants. Cancer Res 1968; 28:
2496–2501.
91. Lin Y, McKinnon KE, Ha SW, Beck GRJ. Inorganic phosphate induces cancer cell mediated
angiogenesis dependent on Forkhead Box Protein C2 (FOXC2) regulated osteopontin
expression. Mol Carcinog. (e-pub ahead of print 2 April 2014; doi:10.1002/mc.22153).
92. Jin H, Xu CX, Lim HT, Park SJ, Shin JY, Chung YS et al. High dietary inorganic phosphate
increases lung tumorigenesis and alters Akt signaling. Am J Respir Crit Care Med 2009; 179:
59–68.
93. Ramirez C, Fiedler D. Investigating the role of inorganic phosphate in tumor metabolism and
metastasis. Cancer Metab 2014; 2: 55.
94. Wilson KM, Ma J, Giovannucci E. Abstract B99: Calcium and phosphorus intake and risk of
prostate cancer: A 22-year follow-up study. Cancer Prev Res 2011; 4: B99–B99.
95. Schmitz R. China’s toxic harvest: a ‘cancer village’ rises in protest. In marketplace.org 2013.
96. Abid Z, Cross AJ, Sinha R. Meat, dairy, and cancer. Am J Clin Nutr 2014; 100: 386S–393S.
97. Ismail EA, Al-Mutairi G, Al-Anzy H. A fatal small dose of phosphate enema in a young child with
no renal or gastrointestinal abnormality. J Pediatr Gastroenterol Nutr 2000; 30: 220–221.
98. Perlman JM. Fatal hyperphosphatemia after oral phosphate overdose in a premature infant.
Am J Health Syst Pharm 1997; 54: 2488–2490.
99. Martin RR, Lisehora GR, Braxton Jr. M , Barcia PJ. Fatal poisoning from sodium phosphate
enema. Case report and experimental study. JAMA 1987; 257: 2190–2192.
100. Shutto Y, Shimada M, Kitajima M, Yamabe H, Saitoh Y, Saitoh H et al. Inadequate awareness
among chronic kidney disease patients regarding food and drinks containing artificially added
phosphate. PLoS ONE 2013; 8: e78660.
101. Shutto Y, Shimada M, Kitajima M, Yamabe H, Razzaque MS. Lack of awareness among future
medical professionals about the risk of consuming hidden phosphate-containing processed
food and drinks. PLoS ONE 2011; 6: e29105.
102. Ghosh AK, Joshi SR. Disorders of calcium, phosphorus and magnesium metabolism. J Assoc
Physicians India 2008; 56: 613–621.
103. Palmese S, Pezza M, De Robertis E. Hypophosphatemia and metabolic acidosis. Minerva
Anestesiol 2005; 71: 237–242.
104. Loh TP, Saw S, Sethi SK. Hyperphosphatemia in a 56-year-old man with hypochondrial pain.
Clin Chem 2010; 56: 892–895.
Phosphate toxicity
RB Brown et al
BoneKEy Reports | JUNE 2015 7
